Manama, Dec 15 (IANS) The Bahrain health regulator has announced that it has officially approved the registration of a Covid-19 vaccine developed by the China National Pharmaceutical Group, or Sinopharm, a state media report.
The National Health Regulatory Authority made the decision to approve and use the vaccine after a thorough review and evaluation of the clinical trial data, the Xinhua news agency quoted the report on Monday.
“Results from Phase III clinical trials showed an 86 percent efficacy, a 99 percent seroconversion rate of a neutralizing antibody and a 100 percent efficacy to prevent moderate and severe cases of Covid-19, after testing in 42,299 volunteers,” the report added.
Bahrain, which participated in clinical trials on the Phase III vaccine in August, authorized the emergency use of Sinopharm vaccine in November to cover those front-line professionals in contact with Covid-19 patients.
The country has so far reported 89,268 coronavirus cases and 348 deaths.